Flossbach Von Storch
NVCR icon

Flossbach Von Storch’s NovoCure NVCR Stock Holding History

Flossbach Von Storch’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-33,863
Closed -$395K – 95
2016
Q2 		$395K Buy
+33,863
New +$424K 0.01% 87

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Flossbach Von Storch's NVCR Position: Q3 2016 in Review

Flossbach Von Storch sold out of NovoCure (NVCR) in Q3 2016, closing a stake of 33,863 shares — an estimated $395K sold.

Flossbach Von Storch first reported a position in NVCR in Q2 2016 and held it in 1 quarter. The position peaked at $395K in Q2 2016. 63 funds tracked by Wall St. Rank hold NVCR as of Q3 2016.

  • Flossbach Von Storch reported no remaining NovoCure position as of Q3 2016 after selling out during the quarter.
  • Flossbach Von Storch sold 33,863 NovoCure shares in Q3 2016, an estimated $395K.
  • Flossbach Von Storch first reported a position in NovoCure in Q2 2016 and held it in 1 quarter.
  • Flossbach Von Storch's NovoCure position peaked at $395K in Q2 2016.
  • 63 funds tracked by Wall St. Rank held NovoCure as of Q3 2016.

Based on Flossbach Von Storch's 13F filing for Q3 2016, filed 28 Oct 2016.